Mammoth Biosciences Advances Lead Candidate MB-111 Toward the Clinic with the Presentation of Preclinical Durability and Safety Data at American Heart Association Scientific Sessions 2026

Posted on by sHq_LoGiNz

BRISBANE, Calif.–(BUSINESS WIRE)– #AHA–Durable efficacy and favorable safety profile supports planned 2027 clinical testing in persistent chylomicronemia.

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance (opens in a new tab)
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.